MedinCell's location in Montpellier, France, was a strategic choice, not an accident. The city is a major research hub with a deep history in medicine and pharmacy, home to the "Pope of PLA polymers." This ecosystem provided the foundational science and talent for the company's success.
In the pharma industry, prestige lies in drug development. However, the delivery mechanism is equally crucial for a drug's success, affecting compliance, efficacy, and ultimately, commercial viability. Companies often fail to integrate delivery strategy early enough, but this is starting to shift.
MedinCell's CEO credits his experience running a remote fishing lodge with teaching him essential business skills. The role required managing logistics, HR, finance, and operations for 35 employees and 700 flights in five months, providing a real-world MBA in entrepreneurship.
Unlike typical biotechs, MedinCell developed without venture capital or angel investment. They focused on operating as a commercial entity from the start, “tightening their belt to the tenth degree.” This unconventional path forced extreme capital efficiency but may have slowed talent acquisition.
Rather than just taking market share from existing treatments, successful long-acting injectables expand the total addressable market. Analysts predict they will grow the treated patient population in schizophrenia from 13% to 20% by 2030 by improving compliance and outcomes.
A major competitor, Eli Lilly, previously failed to create a long-acting injectable for the drug olanzapine due to technical issues. This historical failure has deterred other companies, leaving MedinCell with a significant competitive advantage and no direct competition for the foreseeable future.
MedinCell, listed only on Euronext in France, successfully attracted significant US investment by dedicating three years to systematic outreach. This rare achievement involved direct engagement, leading to US funds buying shares directly on the European exchange and attracting US bank analyst coverage.